| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18431 R78037 |
Lee (Controls exposed to TCAs), 2025 | Cesarean delivery | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) |
0.66 [0.39;1.14] C excluded (control group) |
19/81 194/613 | 213 | 81 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18412 R77774 |
Lee (Controls unexposed, general pop), 2025 | Cesarean delivery | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 0.66 [0.40;1.11] | 19/81 111,640/463,440 | 111,659 | 81 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7696 R22838 |
Kivistö, 2016 | Caesarean | during pregnancy (anytime or not specified) | retrospective cohort | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 1.00 [0.70;1.46] | -/215 4,216/24,402 | - | 215 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7179 R20193 |
Colvin, 2011 | Caesarean (emergency and elective) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) | 1.06 [0.94;1.20] C | 379/1,136 29,801/92,995 | 30,180 | 1,136 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18303 R77078 |
Heikkinen, 2002 | Cesarean | during pregnancy (anytime or not specified) | prospective cohort | unexposed (general population or NOS) | Adjustment: No Matched Monotherapy: no or not specified | 0.90 [0.05;16.60] C | 1/11 1/10 | 2 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 1.02 [0.89;1.17] | 141,841 | 1,443 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, general pop;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 18431